Cancer Care

 

 
A Phase III Trial of the Study of Endocrine Therapy Used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the Prostate
Principal Investigator (?)
Study Number
R9408
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Androgens can
stimulate the growth of prostate cancer cells. Hormone therapy using flutamide, goserelin,
and leuprolide may fight prostate cancer by reducing the production of androgens. It is not
yet known which regimen of antiandrogen therapy is most effective for prostate cancer.

PURPOSE: Randomized phase III trial to study the effectiveness of radiation therapy with or
without antiandrogen therapy in treating patients who have stage I or stage II prostate
cancer.
Phase (?)
Phase III
Sponsor (?)
Available at the following location(s)

Southwestern Vermont

View more details from ClinicalTrials.gov.

Contact Information

For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:

Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.